N-(1,2-Diphenylethyl)piperazines: A new class of dual serotonin/noradrenaline reuptake inhibitor

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 16, 2006, Pages 4345-4348

  Jonathan Fray, M ^a   Bish, Gerwyn ^a   Brown, Alan D ^a   Fish, Paul V ^a   Stobie, Alan ^a   Wakenhut, Florian ^a   Whitlock, Gavin A ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Depression; Incontinence; Neurotransmitters; Noradrenaline; Reuptake inhibition; Serotonin

Indexed keywords

DULOXETINE; FLUOXETINE; NORADRENALIN UPTAKE INHIBITOR; PIPERAZINE DERIVATIVE; REBOXETINE; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DESIGN; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; STRUCTURE ACTIVITY RELATION;

AMINES; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; HUMANS; MODELS, CHEMICAL; NOREPINEPHRINE; PIPERAZINES; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; THIOPHENES;

EID: 33745727155     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.05.051     Document Type: Article

References (35)

1. Reith, M. E. A., Ed.; Neurotransmitter Transporters: Structure, Function and Regulation, 2nd ed.; Humana: Totowa, New Jersey, 2002.
2. Iversen L. Mol. Psychiatry 5 (2000) 357
3. Schatzberg A.F. J. Clin. Psychiatry 61 Suppl. 11 (2000) 9
4. Barker E.L., and Blakely R.D. In: Bloom F.E., and Kupfer D.J. (Eds). Psychopharmacology: The Fourth Generation of Progress (1995), Raven Press, Philadelphia 21
5. Pacher P., Kohegiji E., Kecskemeti V., and Furst S. Curr. Med. Chem. 8 (2001) 89
6. Masand P.S., and Gupta S. Harv. Rev. Psychiatry 7 (1999) 69
7. Finley P.R. Ann. Pharmacother. 28 (1994) 1359
8. Page M.E. CNS Drug Rev. 9 (2003) 327
9. Svensson T.H. Acta Psychiatr. Scand. Suppl. 402 (2000) 18
10. Tanum L. Acta Psychiatr. Scand. Suppl. 402 (2000) 37
11. Einarson T.R., Addis A., Mittmann N., and Iskedjian M. Can. J. Clin. Pharmacol. 5 (1998) 205
12. Dubovsky S.L. J. Clin. Psychiatry 55 Suppl. (1994) 34
13. Brunello N., and Racagni G. Human Psychopharmacol. 13 (1998) S13
14. Boot J.R., Brace G., Delatour C.L., Dezutter N., Fairhurst J., Findlay J., Gallagher P.T., Hoes I., Mahadevan S., Mitchell S.N., Rathwell R.E., Richards S.J., Simmonds R.G., Wallace L., and Whatton M.A. Bioorg. Med. Chem. Lett. 14 (2004) 5395
15. Bymaster F.P., Beedle E.E., Findlay J., Gallagher P.T., Krushinski J.H., Mitchell S.N., Robertson D.W., Thompson D.C., Wallace L., and Wong D.T. Bioorg. Med. Chem. Lett. 13 (2003) 4477
16. Schatzberg A.F. J. Clin. Psychiatry 64 Suppl. 13 (2003) 30
17. Detke M.J., Lu Y., Goldstein D.J., McNamara R.K., and Demitrack M.A. J. Psychiatr. Res. 36 (2002) 383
18. Karpa K.D., Cavanaugh J.E., and Lakiski J.M. CNS Drug Rev. 8 (2002) 361
19. Bump R.C., Norton P.A., Zinner N.R., and Yalcin I. Obstet. Gynecol. 102 (2003) 76
20. Yu P. Curr. Opin. Invest. Drugs 1 (2000) 504
21. Preti A. Curr. Opin. Invest. Drugs 1 (2000) 241
22. Mochizucki D. Human Psychopharmacol. 19 Suppl. 1 (2004) S15
23. James C.K., Peters S.C., and Shannon H.E. J. Pharm. Exp. Ther. 312 (2005) 726
24. Goldstein D.J., Lu Y., Detke M.J., Hudson J., Iyengar S., and Demitrack M.A. Psychosomatics 45 (2004) 17
25. Gundertofte K., Bogeso K.P., and Liljefors T. In: Van de Waterbeemd H., Testa B., and Folkers G. (Eds). Computer-Assisted Lead Finding and Optimization: Current tools for Medicinal Chemistry (1997), Wiley-Verlag, Weinheim 445-459
26. Natsuka K., Nishikawa Y., and Nakamura H. Chem. Pharm. Bull. 47 (1999) 1790
27. Natsuka K., Nakamura H., Negoro T., Uno H., and Nishimura H. J. Med. Chem. 21 (1978) 1265
28. 50 = 4 nM would have 95% confidence intervals of 1.4-6.6 nM.
29. Katritzky A.R., Yannakopoulou K., Lue P., Rasala D., and Urogdi L. J. Chem. Soc., Perkin Trans. 1 (1989) 225
30. Katritzky A.R., Strah S., and Belyakov S.A. Tetrahedron 54 (1998) 7167
31. The organometallic reagents used were either obtained commercially or generated from the commercial benzylic chloride or bromide immediately prior to use.
32. All test compounds were prepared and screened as racemates.
33. Hall J., and Gisler M. J. Org. Chem. 41 (1976) 3769
34. Kidd D.A.A., and Wright D.E. J. Chem. Soc. (1962) 1420
35. Kotturi S.V., Jiang S., Chang A.-C., Abraham P., Navarro H.A., Kuhar M.J., and Carroll F.I. J. Med. Chem. 48 (2005) 7437